Detalles de la búsqueda
1.
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.
Hematol Oncol
; 39(4): 558-566, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34224180
2.
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Br J Haematol
; 189(5): 888-903, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32017044
3.
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.
Leuk Lymphoma
; 62(4): 918-926, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33210570
4.
Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.
Leukemia
; 35(6): 1631-1642, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33980976
5.
A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort.
Hematol Transfus Cell Ther
; 42(1): 46-53, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31235325
6.
A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort
Hematol., Transfus. Cell Ther. (Impr.)
; 42(1): 46-53, Jan.-Mar. 2020. tab, graf
Artículo
en Inglés
| LILACS | ID: biblio-1090480
Resultados
1 -
6
de 6
1
Próxima >
>>